Trial of controversial Alzheimer’s drug halted after disappointing results

Cassava Sciences announced Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer’s disease in the trial.

Source

(Except for the headline, this story has not been edited by PostX News and is published from a syndicated feed.)